Physicians Realty Trust (NYSE: DOC) – Capital One Financial stock analysts lowered their Q3 2021 earnings per share (EPS) estimates for shares of Physicians Realty Trust in a research report released to clients and investors on Monday, October 4. Capital One Financial analyst D. Bernstein now predicts the REIT will post earnings per share of $ 0.26 for the quarter, down from its previous estimate of $ 0.27. Capital One Financial also released estimates for Physicians Realty Trust’s fourth quarter 2021 earnings at $ 0.27 per share, second quarter 2022 earnings at $ 0.27 per share, third quarter 2022 earnings at 0, $ 27 per share, fourth quarter 2022 earnings at $ 0.28 per share, and full year 2022 earnings at $ 1.09 per share. Physicians Realty Trust (NYSE: DOC) last released its quarterly earnings data on Wednesday, August 4. The real estate investment trust reported earnings per share of $ 0.08 for the quarter, missing the Thomson Reuters consensus estimate of $ 0.27 ($ 0.19). Physicians Realty Trust had a net margin of 15.47% and a return on equity of 2.53%. The company posted revenue of $ 112.93 million for the quarter, compared to analysts’ estimates of $ 114.37 million. During the same period last year, the company made EPS of $ 0.27. The company’s turnover increased by 3.5% compared to the same quarter last year.
A number of other research analysts have also recently commented on the headline. Morgan Stanley downgraded Physicians Realty Trust’s stock rating from “overweight” to “equal weight” and set a price target of $ 20.00 for the company. in a report on Monday, September 13. Zacks Investment Research downgraded Physicians Realty Trust shares from a “hold” rating to a “sell” rating in a report released on Wednesday, August 25. Raymond James downgraded Physicians Realty Trust shares from an “outperformance” rating to a “market performance” rating in a Friday August 20 research note. Colliers Securities reaffirmed a “buy” note and issued a price target of $ 21.00 on shares of Physicians Realty Trust in a report released on Friday, July 16. Finally, Robert W. Baird downgraded Physicians Realty Trust’s stock rating from an “outperforming” to a “neutral” rating and raised his price target for the company from $ 19.00 to $ 20.00 in a report published on Monday, June 14. One research analyst rated the stock with a sell rating, four assigned a conservation rating, and three issued a buy rating for the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $ 20.33.
NYSE DOC opened at $ 17.72 on Wednesday. The company has a leverage ratio of 0.48, a current ratio of 2.03, and a rapid ratio of 2.03. The stock has a market cap of $ 3.85 billion, a price-to-earnings ratio of 56.84, a PEG ratio of 2.51, and a beta of 0.81. Physicians Realty Trust has a one-year minimum of $ 16.48 and a one-year maximum of $ 20.13. The company’s fifty-day average mobile price is $ 18.44, and its 200-day average mobile price is $ 18.49.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 15. Shareholders of record on Monday, October 4 will receive a dividend of $ 0.23. This represents an annualized dividend of $ 0.92 and a return of 5.19%. The ex-dividend date is Friday October 1. Physicians Realty Trust’s payout ratio is currently 87.62%.
A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Parametric Portfolio Associates LLC increased its stake in Physicians Realty Trust shares by 7.8% during the second quarter. Parametric Portfolio Associates LLC now owns 506,305 Real Estate Investment Trust shares worth $ 9,351,000 after purchasing an additional 36,610 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new equity stake in Physicians Realty Trust in the second quarter valued at $ 192,000. Heitman Real Estate Securities LLC increased its stake in Physicians Realty Trust shares by 42.2% in the second quarter. Heitman Real Estate Securities LLC now owns 3,465,059 real estate investment trust shares valued at $ 64,000,000 after purchasing an additional 1,027,795 shares during the period. Mariner LLC increased its stake in Physicians Realty Trust shares by 2.4% in the second quarter. Mariner LLC now owns 23,159 real estate investment trust shares valued at $ 428,000 after purchasing an additional 552 shares during the period. Finally, Morgan Stanley increased its stake in Physicians Realty Trust by 107.5% during the second quarter. Morgan Stanley now owns 1,880,605 real estate investment trust shares valued at $ 34,735,000 after acquiring an additional 974,350 shares in the last quarter. 86.56% of the shares are currently held by institutional investors and hedge funds.
About Physicians Realty Trust
Physicians Realty Trust is a real estate investment trust engaged in the acquisition, development, ownership and management of healthcare properties. Its main investments include medical office buildings; outpatient treatment facilities; acute and post-acute care hospitals; as well as other real estate that is an integral part of health care providers.
Recommended Story: How to start trading in the forex market?
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should You Invest $ 1,000 In Physicians Realty Trust Now?
Before you consider Physicians Realty Trust, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Physicians Realty Trust was not on the list.
While Physicians Realty Trust currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here